Larimar Therapeutics (LRMR) Stock Overview
A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LRMR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Larimar Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$1.61 |
| Beta | 0.94 |
| 1 Month Change | 21.50% |
| 3 Month Change | 89.32% |
| 1 Year Change | -50.57% |
| 3 Year Change | 32.65% |
| 5 Year Change | -67.77% |
| Change since IPO | -68.29% |
Recent News & Updates
Recent updates
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
May 28
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Jan 03We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Dec 18Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Oct 07Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans
Aug 09Larimar Therapeutics: More Data Still Needed
Jul 15Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
May 31We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Shareholder Returns
| LRMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | 3.8% | 1.3% |
| 1Y | -50.6% | -8.1% | 15.8% |
Return vs Industry: LRMR underperformed the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: LRMR underperformed the US Market which returned 16.1% over the past year.
Price Volatility
| LRMR volatility | |
|---|---|
| LRMR Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LRMR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LRMR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 65 | Carole Ben-Maimon | larimartx.com |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. Fundamentals Summary
| LRMR fundamental statistics | |
|---|---|
| Market cap | US$343.22m |
| Earnings (TTM) | -US$99.79m |
| Revenue (TTM) | n/a |
Is LRMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LRMR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$99.79m |
| Earnings | -US$99.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LRMR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 21:37 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Larimar Therapeutics, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |